Herein, to avoid the drawbacks from virus vectors, we used HPAEs as delivery carriers for the CRISPR-Cas9 system to develop a potential topical treatment for RDEB patients having mutations in COL7A1 exon 80. The gene discussed is COL7A1; the disease is recessive dystrophic epidermolysis bullosa.